March 5 (SeeNews) - North Macedonia's pharmaceuticals producer Replek [MSE:REPL] made a consolidated net profit of 280.6 million denars ($4.9 million/4.6 million euro) last year, significantly higher compared with 81.9 million denars booked the previous year.
Total operating revenues went up 37% year-on-year to 1.9 billion denars in 2023, while total operating costs were 30% higher at 1.6 billion denars, Replek said in an annual financial statement last week.
Replek's shares last traded on the Macedonian Stock Exchange (MSE) at an average price of 101,000 denars on March 1, bourse data shows.
(1 euro = 61.62 denars)